Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Blood (2022) 139 (14): 2198–2211.

https://doi.org/10.1182/blood.2021013442

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Allison Barz Leahy, Kaitlin J. Devine, Yimei Li, Hongyan Liu, Regina Myers, Amanda DiNofia, Lisa Wray, Susan R. Rheingold, Colleen Callahan, Diane Baniewicz, Maria Patino, Haley Newman, Stephen P. Hunger, Stephan A. Grupp, David M. Barrett, Shannon L. Maude

Blood (2022) 139 (14): 2173–2185.

https://doi.org/10.1182/blood.2021012727

Published: 2022

Includes: Supplemental data

Journal Articles

Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia

Blood (2021) 138 (Supplement 1): 2203.

https://doi.org/10.1182/blood-2021-146102

Published: 2021

Journal Articles

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Joseph H Oved, Caitlin W Elgarten, Yongping Wang, Stephan Kadauke, Dimitri S. Monos, David M. Barrett, Stephan A. Grupp, Nancy Bunin, Timothy S. Olson

Blood (2021) 138 (Supplement 1): 171.

https://doi.org/10.1182/blood-2021-154305

Published: 2021

Journal Articles

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

Sherly Mardiana, Olga Shestova, Stephan A. Grupp, Marco Ruella, David M. Barrett, Saar Gill

Blood (2021) 138 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2021-146995

Published: 2021

Journal Articles

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136860

Published: 2020

Journal Articles

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Jr, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar I. Gill

Blood (2020) 135 (7): 505–509.

https://doi.org/10.1182/blood.2019001859

Published: 2020

Includes: Supplemental data

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Allison Barz Leahy, MD, Kaitlin J. Stanley, MD, Regina M. Myers, MD, Amanda M. DiNofia, MD, Lisa Wray, MD, Susan R. Rheingold, MD, Colleen Callahan, CRNP, Diane Baniewicz, CRNP, Amy E. Barry, PPCNP-BC, Maria M. Patino, BS, Stephen P. Hunger, MD, Stephan Grupp, MD PhD, David M. Barrett, Shannon L. Maude, MD PhD

Blood (2019) 134 (Supplement_1): 1464.

https://doi.org/10.1182/blood-2019-130060

Published: 2019

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Getting the most from your CAR target

David M. Barrett

Blood (2018) 132 (14): 1467–1468.

https://doi.org/10.1182/blood-2018-08-869552

Published: 2018

Journal Articles

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

Blood (2018) 131 (9): 995–999.

https://doi.org/10.1182/blood-2017-07-794214

Published: 2018

Includes: Supplemental data

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

Targetting CD38 in T Cell Acute Lymphoblastic Leukemia

Karen L. Bride, MD PhD, Tiffaney L. Vincent, Soo-Yeon Im, David M. Barrett, Michelle L. Hermiston, MD PhD, Terzah M. Horton, MD PhD, Mignon L. Loh, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Brent Wood, MDPhD, David T Teachey, MD

Blood (2017) 130 (Supplement 1): 3888.

https://doi.org/10.1182/blood.V130.Suppl_1.3888.3888

Published: 2017

Journal Articles

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Marco Ruella, MD, David M. Barrett, Olga Shestova, PhD, Jessica Perazzelli, PhD, Avery D. Posey, PhD, Miroslaw Kozlowski, PhD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 4463.

https://doi.org/10.1182/blood.V130.Suppl_1.4463.4463

Published: 2017

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function

David M. Barrett, MD PhD, Nathan Singh, MD, Ted J. Hofmann, PhD, Zachary Gershenson, Stephan A. Grupp, MD PhD

Blood (2016) 128 (22): 654.

https://doi.org/10.1182/blood.V128.22.654.654

Published: 2016

Journal Articles

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Saba Ghassemi, PhD, Patel Prachi, John Scholler, Selene Nunez-Cruz, PhD, David M. Barrett, MD PhD, Felipe Bedoya, PhD, Joseph A. Fraietta, PhD, Simon Francis Lacey, PhD BS, Bruce L Levine, PhD, Stephen A. Grupp, MD PhD, Carl H June, MD, Michael C. Milone, MD PhD, J. Joseph Melenhorst, PhD

Blood (2016) 128 (22): 4549.

https://doi.org/10.1182/blood.V128.22.4549.4549

Published: 2016

Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 217.

https://doi.org/10.1182/blood.V128.22.217.217

Published: 2016

NARROW

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia

Ex Vivo T-Cell Receptor αβ + /CD19 + depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation

Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Getting the most from your CAR target

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Targetting CD38 in T Cell Acute Lymphoblastic Leukemia

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only